Solventum Corp(SOLV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 10 | EPS (ttm) | 8.18 | Insider Own | 15.33% | Shs Outstand | 170.1M | Perf Week | -5.56% |
| Market Cap | 13.93B | Forward P/E | 11.16 | EPS next Y | 2.51% | Insider Trans | - | Shs Float | 144.1M | Perf Month | -8.36% |
| Enterprise Value | 18.82B | PEG | 1.15 | EPS next Q | 1.34 | Inst Own | 76.65% | Short Float | 3.44% | Perf Quarter | -5.72% |
| Income | 1.43B | P/S | 1.68 | EPS this Y | 17.1% | Inst Trans | -1.15% | Short Ratio | 4.63 | Perf Half Y | 23.1% |
| Sales | 8.31B | P/B | 2.9 | EPS next 5Y | 9.69% | ROA | 9.78% | Short Interest | 4.95M | Perf YTD | 3.29% |
| Book/sh | 28.22 | P/C | 34.57 | EPS past 3/5Y | 4.51% 1.23% | ROE | 33.96% | 52W High | -13.07% ($94.16) | Perf Year | 15.41% |
| Cash/sh | 2.37 | P/FCF | - | Sales past 3/5Y | 0.79% 0.47% | ROIC | 14.97% | 52W Low | 31.21% ($62.38) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 15.89 | EPS Y/Y TTM | 277.21% | Gross Margin | 55.21% | Volatility(W/M) | 2.55% 2.41% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.26 | Sales Y/Y TTM | -1.18% | Oper. Margin | 8.48% | ATR (14) | 2.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.74 | EPS Q/Q | 3.35% | Profit Margin | 17.26% | RSI (14) | 33.35 | Recom | 2.31 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.02 | Sales Q/Q | 1.19% | SMA20 | -5.07% ($86.22) | Beta | 0.71 | Target Price | $96.27 |
| Payout | - | Debt/Eq | 1.1 | Earnings | 2026/11/5 | SMA50 | -7.33% ($88.32) | Rel Volume | 1.46 | Prev Close | $82.98 |
| Employees | 20000 | LT Debt/Eq | 1 | EPS/Sales Surpr. | 33.89% 2.55% | SMA200 | 4.47% ($78.35) | Avg Volume(3M) | 1.07M | Price | $81.85 |
| IPO | 2024/3/26 | Option/Short | Yes/Yes | Trades | 14823 | Volume | 1,565,371 | Change | -1.36% |
Solventum is a U.S. healthcare company that provides medical and surgical supplies, dental solutions, and health information systems. It was spun off from 3M in 2024 and listed as an independent company, specializing in medical devices and consumables, with a high proportion of its revenue coming from recurring purchases of consumable products.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
Traded more than usual. That is 146% of its average volume.
Next earnings report: November 5
7 days to go.
SOLV makes money exceptionally well
Of every $100 in sales, $8.48 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.1% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $1,116. Peers typically go for $1,892. It is about in line with its own 3-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 76.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #7 of 51 in the industry
Based on market cap of $14B.
SOLV#7 Solventum Corp $14B PER 10.0 
BAX#8 Baxter International Inc $13B PER - 
RGEN#9 Repligen Corp $12B PER - 
COO#10 Cooper Companies Inc $11B PER 20.3 
AVTR#11 Avantor Inc $11B PER 33.6 
FAQ
What kind of company is SOLV?
SOLV belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of SOLV?
The market cap of SOLV is approximately $13.9B, ranking 742 within its sector.
What is the P/E ratio of SOLV?
SOLV has a P/E ratio of approximately 10.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SOLV?
SOLV has recorded a 52-week high of $94.16 and a low of $62.38.
